CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Current Assets:
Cash and cash equivalents	$ 4,237	$ 2,385
Marketable securities, current	2,113	1,885
Receivables	5,543	4,299
Inventories	1,241	1,221
Prepaid expenses and other	570	625
Total Current Assets	13,704	10,415
Property, plant and equipment	4,980	4,412
Goodwill	6,875	6,881
Other intangible assets	1,385	1,419
Deferred income taxes	2,996	2,844
Marketable securities, noncurrent	2,719	4,660
Other assets	1,048	1,117
Total Assets	33,707	31,748
Current Liabilities:
Short-term borrowings and current portion of long-term debt	992	139
Accounts payable	1,664	1,565
Accrued liabilities	5,271	4,738
Deferred income, current	762	1,003
Income taxes payable, current	152	572
Total Current Liabilities	8,841	8,017
Deferred income, noncurrent	547	586
Income taxes payable, noncurrent	973	742
Pension and other liabilities	1,283	1,429
Long-term debt	5,716	6,550
Total Liabilities	17,360	17,324
Commitments and contingencies (Note 18)
Bristol-Myers Squibb Company Shareholders' Equity:
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 4,129 in 2016 and 4,161 in 2015, liquidation value of $50 per share	0	0
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2016 and 2015	221	221
Capital in excess of par value of stock	1,725	1,459
Accumulated other comprehensive loss	(2,503)	(2,468)
Retained earnings	33,513	31,613
Less cost of treasury stock - 536 million common shares in 2016 and 539 million in 2015	(16,779)	(16,559)
Total Bristol-Myers Squibb Company Shareholders' Equity	16,177	14,266
Noncontrolling interest	170	158
Total Equity	16,347	14,424
Total Liabilities and Equity	$ 33,707	$ 31,748